https://openbell.ai/ 2026-10-19T17:37:08.031Z hourly 1.0 https://openbell.ai/support 2026-10-19T17:37:08.031Z monthly 0.7 https://openbell.ai/privacy 2026-10-19T17:37:08.031Z monthly 0.5 https://openbell.ai/terms 2026-10-19T17:37:08.031Z monthly 0.5 https://openbell.ai/feed.json 2026-10-19T17:37:08.031Z hourly 0.8 https://openbell.ai/news/NI:1792431062758 2026-10-19T17:31:02.758Z daily 0.9 https://cdn.brandfetch.io/NI/w/400/h/400?c=1idopYfmtR7ZKg8QMud BMO Capital Maintains Outperform on NiSource, Raises Price Target to $48 BMO Capital analyst James Thalacker has maintained an Outperform rating on NiSource (NYSE: NI) and increased the price target from $45 to $48. This adjustment reflects a positive outlook for the company in the market. https://openbell.ai/news/ASTS:1792430919975 2026-10-19T17:28:39.975Z daily 0.9 https://cdn.brandfetch.io/ASTS/w/400/h/400?c=1idopYfmtR7ZKg8QMud AST SpaceMobile shares are trading higher after the company announced its mobile network operator partners Deutsche Telekom, Orange, Telefónica, and Vodafone signed a letter of intent to explore a potential joint bid for MSS spectrum in Europe. openbell Financial News https://openbell.ai/news/CMS:1792430852788 2026-10-19T17:27:32.788Z daily 0.9 https://cdn.brandfetch.io/CMS/w/400/h/400?c=1idopYfmtR7ZKg8QMud BMO Capital Maintains Outperform on CMS Energy, Raises Price Target to $76 BMO Capital analyst James Thalacker has maintained an Outperform rating on CMS Energy (NYSE: CMS) and raised the price target from $73 to $76. This adjustment reflects a positive outlook for the company in the market. https://openbell.ai/news/VOYG:1792430603091 2026-10-19T17:23:23.091Z daily 0.9 https://cdn.brandfetch.io/VOYG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Morgan Stanley Maintains Underweight on Voyager Technologies, Lowers Price Target to $36 Morgan Stanley analyst Kristine Liwag has maintained an Underweight rating on Voyager Technologies (NYSE: VOYG) and has reduced the price target from $37 to $36. https://openbell.ai/news/TEAM:1792430593315 2026-10-19T17:23:13.315Z daily 0.9 https://cdn.brandfetch.io/TEAM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Atlassian shares are trading higher after Guggenheim maintained its Buy rating on the stock and raised its price target from $165 to $280. Also, Keybanc maintained its Overweight rating and raised its price target from $185 to $235. openbell Financial News https://openbell.ai/news/VSXY:1792430550091 2026-10-19T17:22:30.091Z daily 0.9 https://cdn.brandfetch.io/VSXY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Morgan Stanley Maintains Overweight on Victoria's Secret, Raises Price Target to $104 Morgan Stanley analyst Alex Straton has maintained an Overweight rating on Victoria's Secret (NYSE: VSXY) and raised the price target from $101 to $104. This adjustment reflects a positive outlook for the company's stock performance. https://openbell.ai/news/WMT:1792430233750 2026-10-19T17:17:13.750Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Walmart-Issues-Urgent-Recall-Warning-For.jpg?width=250&height=187 Analyst Sees Billions in Walmart's Next Big Advertising Opportunity Walmart Inc. (NYSE: WMT) is expected to unlock billions in advertising revenue as it expands its digital advertising business and integrates AI into shopping, according to Bank of America analyst Christopher Nardone, who maintains a Buy rating with a $126 price target. The retailer's access to 150 million weekly shoppers and the addition of third-party marketplace sellers are key factors driving advertising growth. Walmart's acquisitions of Vizio and Vibe.co are also anticipated to create multibillion-dollar opportunities in connected TV advertising. However, potential risks include slowing food inflation and increased competition. https://openbell.ai/news/EYPT:1792430199372 2026-10-19T17:16:39.372Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Eye-In-Close-Up-With-Light-Blue-Iris-Det.jpg?width=250&height=187 EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus EyePoint Inc. (NASDAQ: EYPT) is reducing its workforce by 53% and halting its clinical trials for wet age-related macular degeneration after its LUCIA Phase 3 trial failed to meet primary endpoints. The company will redirect its resources towards developing the DURAVYU treatment for diabetic macular edema, which has shown positive secondary outcomes in previous trials. The workforce reduction is expected to save approximately $30 million annually, although it will incur $9 million in one-time severance costs. Following these announcements, EyePoint's stock price fell 85.46% to $0.43, marking a new 52-week low. https://openbell.ai/news/CRMD:1792430121103 2026-10-19T17:15:21.103Z daily 0.9 https://cdn.brandfetch.io/CRMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on Cormedix, Maintains $15 Price Target Needham analyst Serge Belanger has reiterated a Buy rating on Cormedix (NASDAQ: CRMD) and maintained a price target of $15 for the stock. This endorsement reflects confidence in the company's performance and potential for growth. https://openbell.ai/news/DKNG:1792430034838 2026-10-19T17:13:54.838Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Spokane--Wausa---June-2020-View-Of-Draft.jpg?width=250&height=187 Why Is DraftKings Stock Surging on Monday? DraftKings Inc. (NASDAQ: DKNG) shares rose 3.28% to $19.52 on Monday, following an increase in price target to $30 by Wells Fargo, which maintained its Overweight rating. The stock is recovering from a 52-week low of $18.35 and is supported by a consensus of 27 analysts who have a Buy rating, with an average price target of $34 indicating a potential upside of 76.4%. Investors are anticipating the company's earnings report on November 5, with expectations of a loss of 36 cents per share and revenue growth to $1.40 billion from $1.14 billion a year earlier. https://openbell.ai/news/OCUL:1792429958941 2026-10-19T17:12:38.941Z daily 0.9 https://cdn.brandfetch.io/OCUL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target Needham analyst Serge Belanger has reiterated a Buy rating on Ocular Therapeutix (NASDAQ: OCUL) and maintained a price target of $18 for the company's stock. https://openbell.ai/news/MGM:1792429808795 2026-10-19T17:10:08.795Z daily 0.9 https://cdn.brandfetch.io/MGM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Morgan Stanley Maintains Underweight on MGM Resorts International, Lowers Price Target to $29 Morgan Stanley analyst Stephen Grambling has maintained an Underweight rating on MGM Resorts International (NYSE: MGM) and has reduced the price target from $43 to $29. https://openbell.ai/news/SYRE:1792429771374 2026-10-19T17:09:31.374Z daily 0.9 https://cdn.brandfetch.io/SYRE/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target BTIG analyst Julian Harrison has reiterated a 'Buy' rating on Spyre Therapeutics (NASDAQ: SYRE) and has maintained a price target of $121 for the stock. This endorsement suggests confidence in the company's future performance. https://openbell.ai/news/META:1792429731126 2026-10-19T17:08:51.126Z daily 0.9 https://cdn.brandfetch.io/META/w/400/h/400?c=1idopYfmtR7ZKg8QMud Morgan Stanley Maintains Overweight on Meta Platforms, Raises Price Target to $820 Morgan Stanley analyst Brian Nowak has maintained an Overweight rating on Meta Platforms (NASDAQ: META) and increased the price target from $775 to $820. This adjustment reflects positive expectations for the company's performance. https://openbell.ai/news/DXC:1792429714217 2026-10-19T17:08:34.217Z daily 0.9 https://cdn.brandfetch.io/DXC/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'DXC in advanced talks to sell insurance software unit for $2.4 billion, sources say' - Reuters DXC Technology is reportedly in advanced discussions to sell its insurance software unit for approximately $2.4 billion. This potential sale reflects the company's strategic focus on streamlining operations and enhancing its core business. The transaction could significantly impact DXC's financial position and market strategy. https://openbell.ai/news/NXST:1792429668267 2026-10-19T17:07:48.267Z daily 0.9 https://cdn.brandfetch.io/NXST/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Nexstar asks FCC to reject stay of national TV ownership cap repeal' - TheDesk.net Nexstar Media Group has requested the Federal Communications Commission (FCC) to reject a stay on the repeal of the national television ownership cap. This move is part of Nexstar's strategy to expand its media operations and consolidate its market presence. The outcome of this request could significantly impact the company's growth and competitive positioning in the broadcasting industry. https://openbell.ai/news/XHG:1792429550025 2026-10-19T17:05:50.025Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=250&height=187 12 Financials Stocks Moving In Monday's Intraday Session On Monday, XChange Tec (NASDAQ:XHG) shares surged 37.0% to $2.74, with a market cap of $87.1 million. Atlantic American (NASDAQ:AAME) also saw a significant increase of 36.3% to $1.43, following the release of its Q4 earnings, and has a market cap of $21.6 million. Conversely, SHF Hldgs (NASDAQ:SHFS) experienced the largest decline, falling 34.1% to $0.09. Other notable losers included House of Doge (NASDAQ:HODO), which dropped 24.47% to $0.07, and Zhibao Technology (NASDAQ:ZBAO), down 20.03% to $0.51. https://openbell.ai/news/SLN:1792429549743 2026-10-19T17:05:49.743Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=250&height=187 12 Health Care Stocks Moving In Monday's Intraday Session Silence Therapeutics (NASDAQ: SLN) saw a significant stock increase of 125.6% to $19.59, with a market value of $581.1 million. Other notable gainers included SCWorx (NASDAQ: WORX) up 80.32% to $2.49, and Disc Medicine (NASDAQ: IRON) up 40.01% to $79.58, with a market cap of $2.1 billion. Conversely, EyePoint (NASDAQ: EYPT) experienced a sharp decline of 85.7% to $0.43, while Matinas BioPharma Holdings (AMEX: MTNB) fell 33.34% to $1.58. https://openbell.ai/news/EXYN:1792429549390 2026-10-19T17:05:49.390Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_4.jpg?width=250&height=187 12 Industrials Stocks Moving In Monday's Intraday Session During Monday's trading session, Exyn Technologies (NASDAQ: EXYN) saw its shares rise by 22.2% to $2.40, with a market capitalization of $15.9 million. Other notable gainers included Amaero (NASDAQ: AMRO), which increased by 16.88% to $5.26, and CDT Environmental Tech (NASDAQ: CDTG), which rose 15.04% to $1.19. Conversely, INLIF (NASDAQ: INLF) experienced a significant decline of 87.5%, dropping to $0.32, with a market cap of $2.8 million. https://openbell.ai/news/FUFU:1792429549149 2026-10-19T17:05:49.149Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=250&height=187 12 Information Technology Stocks Moving In Monday's Intraday Session On Monday, BitFuFu (NASDAQ:FUFU) saw a significant stock increase of 37.8%, reaching $1.24, with a market capitalization of $218.3 million. Other notable gainers included Bitzero Holdings (NASDAQ:AIBZ) with a 27.89% rise to $2.98 and 3 E Network (NASDAQ:MASK) up 24.48% to $1.0. Conversely, Sangrix (NASDAQ:SGRX) experienced a sharp decline of 40.0%, dropping to $0.52, while Amplitech Group, Inc. - Series B Right (NASDAQ:AMPGZ) fell by 31.11% to $0.07. https://openbell.ai/news/FDXF:1792429494710 2026-10-19T17:04:54.710Z daily 0.9 https://cdn.brandfetch.io/FDXF/w/400/h/400?c=1idopYfmtR7ZKg8QMud FedEx Freight Holding shares are trading lower after Stifel lowered its price target on the stock from $160 to $129. openbell Financial News https://openbell.ai/news/SLN:1792429369060 2026-10-19T17:02:49.060Z daily 0.9 https://cdn.brandfetch.io/SLN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is Silence Therapeutics Stock Skyrocketing Monday? Silence Therapeutics plc (NASDAQ: SLN) announced its acquisition by Merck KGaA for approximately $1.3 billion in cash, leading to a nearly 126% surge in its stock price to $19.58. The deal, which offers $20 per American depositary share (ADS), represents a 130% premium over Silence's closing price prior to the announcement. The acquisition is expected to close in early 2027, subject to regulatory approvals, and will enhance Merck KGaA's portfolio in rare diseases, particularly through Silence's experimental drug, divesiran. https://openbell.ai/news/SLN:1792429362274 2026-10-19T17:02:42.274Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Merger-And-Acquisition-Business-Corporat.jpg?width=250&height=187 Why Is Silence Therapeutics Stock Skyrocketing Monday? Silence Therapeutics plc (NASDAQ: SLN) announced a $1.3 billion acquisition by Merck KGaA, which will pay $20 per American depositary share, representing a 130% premium over Silence's closing price prior to the announcement. Following the news, Silence's stock surged nearly 126%, reaching a new 52-week high with trading volume spiking to 57.883 million shares. The deal, expected to close in early 2027, will enhance Merck KGaA's rare disease pipeline, particularly through Silence's experimental drug divesiran, which targets polycythemia vera. https://openbell.ai/news/LYV:1792429333702 2026-10-19T17:02:13.702Z daily 0.9 https://cdn.brandfetch.io/LYV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Morgan Stanley Maintains Overweight on Live Nation Entertainment, Raises Price Target to $215 Morgan Stanley analyst Cameron Mansson-Perrone has maintained an Overweight rating on Live Nation Entertainment (NYSE: LYV) and increased the price target from $200 to $215. This adjustment reflects positive expectations for the company's performance in the market. https://openbell.ai/news/ARQT:1792429332901 2026-10-19T17:02:12.901Z daily 0.9 https://cdn.brandfetch.io/ARQT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Arcutis Biotherapeutics shares are trading higher after Guggenheim raised its price target on the stock from $38 to $44. openbell Financial News https://openbell.ai/news/SLN:1792429283580 2026-10-19T17:01:23.580Z daily 0.9 https://cdn.brandfetch.io/SLN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is Silence Therapeutics Stock Skyrocketing Monday? Silence Therapeutics plc (NASDAQ: SLN) announced an acquisition by Merck KGaA for approximately $1.3 billion in cash, leading to a nearly 126% surge in its stock price to $19.58. The deal offers $20 per American depositary share, representing a 130% premium over its previous closing price. The acquisition will enhance Merck KGaA's rare disease pipeline, particularly through Silence's divesiran drug, which targets polycythemia vera. The transaction is expected to close in early 2027, pending regulatory approvals. https://openbell.ai/news/SLN:1792429223020 2026-10-19T17:00:23.020Z daily 0.9 https://cdn.brandfetch.io/SLN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is Silence Therapeutics Stock Skyrocketing Monday? Silence Therapeutics plc (NASDAQ: SLN) announced a $1.3 billion acquisition by Merck KGaA, which will pay $20 per American depositary share, representing a 130% premium over Silence's closing price prior to the announcement. Following the news, Silence's stock surged nearly 126%, with trading volume reaching 57.883 million shares, significantly higher than its 100-day average of 1.187 million shares. The deal is expected to close in early 2027, pending regulatory and shareholder approvals, and will enhance Merck KGaA's portfolio in rare diseases, particularly through Silence's experimental drug, divesiran. https://openbell.ai/news/ASTS:1792429210576 2026-10-19T17:00:10.576Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Los-Angeles--California---July-8-2025-As.jpg?width=250&height=187 AST SpaceMobile Targets 500 Million Subscribers Through European Carrier Partnership AST SpaceMobile, Inc. (NASDAQ: ASTS) has entered a letter of intent with major European carriers including Deutsche Telekom, Orange, Telefónica, and Vodafone Group to explore a joint bid for European Mobile Satellite Services spectrum, aiming to enhance connectivity for over 500 million subscribers. The company's technology, which connects directly to standard smartphones, has demonstrated download speeds of up to 98.9 Mbps, with future models expected to reach nearly 200 Mbps. Following this announcement, ASTS shares rose by 6.86% to $43.45, while the company anticipates a revenue increase to $46.30 million for its upcoming earnings report on November 9, 2026, compared to $14.74 million year-over-year. https://openbell.ai/news/WERN:1792429126887 2026-10-19T16:58:46.887Z daily 0.9 https://cdn.brandfetch.io/WERN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Werner Enterprises shares are trading lower after the company announced preliminary Q3 revenue of ~$946 million to $951 million and adjusted EPS of ~$0.15 to $0.16, with results hurt by higher fuel costs, driver-related investments, and an insurance reserve adjustment. openbell Financial News https://openbell.ai/news/SNDK:1792429102181 2026-10-19T16:58:22.181Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Sandisk-Company-Logo---EK.jpg?width=250&height=187 Stock Market Today: Nasdaq 100 Rises as AI Chip Rout Reverses, SanDisk Jumps 7% On Monday, the Nasdaq 100 rose by 1.7% to 29,699 points, recovering from a previous week's decline of over 4%. SanDisk Corp. saw a significant increase of nearly 7%, while other memory stocks like Micron Technology and SK Hynix also posted gains. The S&P 500 and Russell 2000 advanced by 0.7% and 0.6%, respectively, as technology stocks led the market rebound amid rising Treasury yields, which increased by about 6 basis points to 5.14%. https://openbell.ai/news/DOGEUSD:1792428852383 2026-10-19T16:54:12.383Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Dogecoin-Doge-Isolated-On-White-Backgrou.jpg?width=250&height=187 Dogecoin Flashes Buy Signal at $0.08 as Whales Accumulate: What’s Next? Dogecoin (DOGE) is currently showing signs of a potential rebound from the $0.08 support level, with analysts noting that the TD Sequential indicator has flashed a buy signal. On-chain data indicates that approximately 36 billion DOGE changed hands around this price, and whales have accumulated about 600 million DOGE since October 12. If the support holds, a rebound towards $0.17 is anticipated, although there is significant overhead supply at that level due to nearly 14 billion DOGE acquired around $0.17. https://openbell.ai/news/NGG:1792428791493 2026-10-19T16:53:11.493Z daily 0.9 https://cdn.brandfetch.io/NGG/w/400/h/400?c=1idopYfmtR7ZKg8QMud National Grid shares are trading lower. Reports suggest that UK Power Networks told Nscale that electricity connection for its data center in Essex may not be available until the early to mid 2030s, which may be eroding sentiment in the broader UK electricity sector. openbell Financial News https://openbell.ai/news/GLW:1792428733132 2026-10-19T16:52:13.132Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Person-Holding-Mobile-Phone-Displaying-C.jpg?width=250&height=187 Can Meta’s Fiber Partner Corning Capitalize On Rising AI Fiber Prices? Corning Incorporated (NYSE: GLW) is positioned to benefit from rising prices of specialized optical fiber, which are expected to average over five times their 2025 levels this year. The company has a $6 billion supply agreement with Meta Platforms Inc. that runs through 2030, contributing to a 32% increase in second-quarter sales to $2.07 billion and a 77% rise in net income to $438 million. Despite a significant drop in share value since June, analysts remain optimistic, with UBS raising its price target to $201 and Citi to $220. https://openbell.ai/news/AAPL:1792428599475 2026-10-19T16:49:59.475Z daily 0.9 https://cdn.brandfetch.io/AAPL/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Apple Announces Oct. 28 Event for Touch-Screen MacBook Pro' - Bloomberg Apple has announced an event scheduled for October 28, 2026, where it is expected to unveil a new touch-screen MacBook Pro. This strategic move indicates Apple's continued innovation in its laptop offerings. The announcement may impact AAPL's stock performance as investors anticipate new product developments. https://openbell.ai/news/DPC:1792428595627 2026-10-19T16:49:55.627Z daily 0.9 https://cdn.brandfetch.io/DPC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Morgan Stanley Maintains Equal-Weight on DPC Holdings, Lowers Price Target to $43 Morgan Stanley analyst Kristine Liwag has maintained an Equal-Weight rating on DPC Holdings (NYSE: DPC) while lowering the price target from $59 to $43. https://openbell.ai/news/AMZN:1792428480274 2026-10-19T16:48:00.274Z daily 0.9 https://cdn.brandfetch.io/AMZN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Amazon.com shares are trading higher after Morgan Stanley maintained an Overweight rating on the stock and raised its price target from $335 to $350. The company announced a partnership with X-Energy and American Electric Power to bring a SMR project to Indiana. openbell Financial News https://openbell.ai/news/MRVL:1792428381994 2026-10-19T16:46:21.994Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/AI-Boosts-Marvell.jpg?width=250&height=187 Why Is Marvell Technology Stock Soaring Monday? Marvell Technology Inc. (NASDAQ: MRVL) stock increased by nearly 7% on Monday, reaching $243.30, as semiconductor stocks rebounded from a previous selloff, with the Nasdaq gaining 1.66%. Analysts maintain a bullish outlook, with a consensus Buy rating and an average price forecast of $348.72, while UBS, Jefferies, and JPMorgan have raised their price targets to $350, $450, and $360 respectively. Despite a strong growth and momentum score, Marvell's price-to-earnings ratio of 75.4 indicates high expectations for future growth, making the stock potentially vulnerable to pullbacks. https://openbell.ai/news/WELL:1792428321003 2026-10-19T16:45:21.003Z daily 0.9 https://cdn.brandfetch.io/WELL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wells Fargo Maintains Overweight on Welltower, Raises Price Target to $268 Wells Fargo analyst James Feldman has maintained an Overweight rating on Welltower (NYSE: WELL) and raised the price target from $266 to $268. This adjustment reflects a positive outlook for the company in the market. https://openbell.ai/news/WMT:1792428312013 2026-10-19T16:45:12.013Z daily 0.9 https://cdn.brandfetch.io/WMT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Live On CNBC, Bill Baruch Announces Bought More Walmart openbell Financial News https://openbell.ai/news/MCD:1792428267745 2026-10-19T16:44:27.745Z daily 0.9 https://cdn.brandfetch.io/MCD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Live On CNBC, Bill Baruch Announces Bought McDonald's openbell Financial News https://openbell.ai/news/DOW:1792428225861 2026-10-19T16:43:45.861Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Stuttgart--Germany---01-27-2023-Person-H.jpg?width=250&height=187 Dow Analyst No Longer Bearish As Earnings Stability Improves BofA Securities analyst Matthew DeYoe upgraded Dow Inc's rating from Underperform to Neutral and raised the price target from $29 to $31, citing improved earnings stability due to stronger petrochemical pricing and demand from China. DeYoe expects Dow's fourth-quarter EBITDA to be $1.454 billion, exceeding the consensus of $1.378 billion, and raised the 2026 EBITDA estimate from $6.053 billion to $6.187 billion. Dow shares rose 0.50% to $29.97 following the announcement. https://openbell.ai/news/NTRA:1792428198676 2026-10-19T16:43:18.676Z daily 0.9 https://cdn.brandfetch.io/NTRA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Natera shares are trading higher after Canaccord maintained its Buy rating on the stock and raised its price target from $375 to $500. openbell Financial News https://openbell.ai/news/IRON:1792428196604 2026-10-19T16:43:16.604Z daily 0.9 https://cdn.brandfetch.io/IRON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study Disc Medicine Inc. (NASDAQ: IRON) announced positive topline results from its APOLLO Phase 3 trial of bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), achieving all primary and secondary endpoints. The trial, involving 183 participants, demonstrated a 41.4% reduction in whole-blood metal-free PPIX and a 12.2-hour increase in light exposure without pain over six months. Following these results, the company plans to resubmit a new drug application to the U.S. FDA by year-end, with a decision expected by mid-2027. Disc Medicine's stock rose 26.07% to $71.66 following the announcement. https://openbell.ai/news/AMZN:1792428121053 2026-10-19T16:42:01.053Z daily 0.9 https://cdn.brandfetch.io/AMZN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Morgan Stanley Maintains Overweight on Amazon.com, Raises Price Target to $350 Morgan Stanley analyst Brian Nowak has maintained an Overweight rating on Amazon.com (NASDAQ: AMZN) and increased the price target from $335 to $350. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/CMG:1792428042749 2026-10-19T16:40:42.749Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Chipotle.jpg?width=250&height=187 Chipotle Q3 Preview: Promos Could Push Comp Positive Despite Food-Safety Drag, Says Bullish Analyst Chipotle Mexican Grill Inc (NYSE: CMG) is set to report its Q3 earnings on October 28, with analysts expecting a same-store sales increase of 1%, up from flat, due to promotional activities offsetting food-safety issues. Analyst Sara Senatore maintained a Buy rating with a price target of $53 and raised the revenue estimate for 2026 from $13.02 billion to $13.05 billion, while keeping the earnings forecast at $1.16 per share. As of the latest data, Chipotle's stock is trading down 1.12% at $29.55. https://openbell.ai/news/AAPL:1792428025973 2026-10-19T16:40:25.973Z daily 0.9 https://cdn.brandfetch.io/AAPL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Apple SVP Marketing Greg Joswiak, On Social Media, Hints At New Product Announcement Next Week Apple's Senior Vice President of Marketing, Greg Joswiak, hinted at a potential new product announcement scheduled for next week via social media. This speculation could impact investor sentiment and stock performance for AAPL as anticipation builds around the new offering. https://openbell.ai/news/TSLA:1792427907265 2026-10-19T16:38:27.265Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Kaunas--Lithuania-2022---April-14-Tesla-.jpg?width=250&height=187 Tesla Stock Trends Higher: What's Going On? Tesla Inc (NASDAQ: TSLA) shares increased by 4.03% to $369.02 ahead of its third-quarter earnings report scheduled for October 21, which is expected to show earnings of 43 cents per share on $27.88 billion in sales. This follows a previous quarter where sales rose 26% to $28.24 billion, but operating income fell 57%. Additionally, speculation surrounding a potential merger with SpaceX has intensified following the recent reveal of Tesla's second-generation Roadster, which incorporates SpaceX technology. Analysts maintain a consensus Buy rating for Tesla, with an average price target of $415. https://openbell.ai/news/WULF:1792427902456 2026-10-19T16:38:22.456Z daily 0.9 https://cdn.brandfetch.io/WULF/w/400/h/400?c=1idopYfmtR7ZKg8QMud TeraWulf shares are trading higher alongside a rally in AI cloud service companies. The CEO posted on social media that TeraWolf is an energy infrastructure company that matches long-term investment-grade energy supplies with long-term HPC/AI offtake. openbell Financial News https://openbell.ai/news/TSLA:1792427695024 2026-10-19T16:34:55.024Z daily 0.9 https://cdn.brandfetch.io/TSLA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Tesla shares are trading higher after reports suggesting that the company's merger with SpaceX may be moving closer to becoming a reality, with prediction market lines for the possibility of that event moving well above 50%. openbell Financial News https://openbell.ai/news/TEAM:1792427671525 2026-10-19T16:34:31.525Z daily 0.9 https://cdn.brandfetch.io/TEAM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Maintains Buy on Atlassian, Raises Price Target to $280 Guggenheim analyst Howard Ma has maintained a Buy rating on Atlassian (NASDAQ: TEAM) and increased the price target from $165 to $280. This adjustment reflects the firm's positive outlook on the company's performance.